Free Trial

Quantum Biopharma Q2 2023 Earnings Report

Quantum Biopharma logo
$4.38 -0.17 (-3.63%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quantum Biopharma EPS Results

Actual EPS
-$9.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Quantum Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quantum Biopharma Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Quantum Biopharma Earnings Headlines

Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

View Quantum Biopharma Profile

More Earnings Resources from MarketBeat